Nurofen introducing the new Sinus range

RB is introducing the Nurofen Sinus Range, comprising Nurofen Sinus & Blocked Nose and Nurofen Sinus Pain Relief, to its leading pain relief portfolio this autumn to help those who suffer with sinus pain and nasal congestion.

5000158106253_T9

The UK decongestant category is currently worth £96m* with 7.3m sinus sufferers. Research shows that nearly all sufferers self-treat and over half treat with an analgesic alone (without a decongestant).**

Over and above cold and flu incidents, patients can suffer from a combination of nasal congestion & sinus pain or sinus pain alone, without other cold symptoms. For many sinus problems occur more frequently and last longer than cough & sore throat – with an average 13 episodes per year.***

The Nurofen Sinus range is the only ibuprofen based Sinus range available at GSL for Sinus pain and congestion. It contains ibuprofen (200mg), which targets pain and has anti-inflammatory properties, combined here with a powerful decongestant (5mg Phenylephrine) which constricts the blood vessels in the nose; this helps open up the nasal passages to make breathing easier, hence providing relief from sinus pain and blocked nose for up to 8h.

Nurofen Sinus & Blocked Nose 16 tablets RRP £5.49

Nurofen Sinus Pain Relief 16 tablets RRP £5.49

Nurofen Sinus & Blocked Nose and Nurofen Sinus Pain Relief will be supported by a £4m promotional campaign launching in October 2015 and scheduled to run until January 2016.

Commenting on the launch Craig Shaw, RB Marketing Director for Nurofen said, ‘This is a significant development for the sinus pain market. We know that there is huge brand loyalty with 66% of shoppers looking for well-known brands that they can trust to be efficacious when they buy their winter medicines. We also know that 75% of shoppers look for specific symptom relief on pack so clear signposting on packaging is key to enabling a customer make an informed purchase. As such we are anticipating high consumer demand for our new Nurofen Sinus products.”

* Nielsen Decon FY 2014

** U&A 2010, Ipsos Mar 2003 – consumer survey amongst 398 patients (95% of sufferers look to treat their symptoms, and that 56% treat with an analgesic).

*** IPSOS Consumer Survey (n=398) March 2003

www.rb.com